Bułgaria - bułgarski - Изпълнителна агенция по лекарствата

actavis group ptc ehf. - l-dopa - 175 mg/43,75 mg/200 mg film - coated tablets

Bułgaria - bułgarski - Изпълнителна агенция по лекарствата

actavis group ptc ehf. - l-dopa - 200 mg/50 mg/200 mg film - coated tablets

Bułgaria - bułgarski - Изпълнителна агенция по лекарствата

Бакстер България ЕООД - Физиологичен разтвор - solution for peritoneal dialysis

Bułgaria - bułgarski - Изпълнителна агенция по лекарствата

Бакстер България ЕООД - Физиологичен разтвор - solution for peritoneal dialysis

Unia Europejska - bułgarski - EMA (European Medicines Agency)

merz pharmaceuticals gmbh - Мемантина донепезил хидрохлорид - Болест на Алцхаймер

Bułgaria - bułgarski - БАБХ (Българска агенция по безопасност на храните)

bioveta, a.s. - dextraferranum - инжекционен разтвор - 100 mg/ml - агнета, говеда, кози, коне, кучета, лисици, норки, овце, прасета, телета

Unia Europejska - bułgarski - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - Карцином, недребноклетъчен белодроб - Други противоракови лекарства, инхибитори на протеинкиназы - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Unia Europejska - bułgarski - EMA (European Medicines Agency)

astrazeneca ab - olaparib - Овариални неоплазми - Антинеопластични средства - Яйчниците cancerlynparza включен като монотерапии за:подкрепа на лечение на възрастни пациенти с късни (фиго етапи iii и iv) в гените brca1/2-мутирали (зародышевой линия и/или соматични) высокосортная епител на яйчника, маточната тръба или начална перитонеална рак, които в отговор (пълна или частична) след приключване на първа линия на базата на платина химиотерапия. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 и 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. Пациентите трябва предварително са обработени с антрациклина и таксана в (нео)помощните или метастатический, ако пациентите не са подходящи за тези процедури (виж раздел 5. Пациентите с рецептор хормон (ч)-положителен рак на гърдата трябва също така да развиват или след предварителна хормонална терапия, или се считат за неподходящи за ендокринна терапия. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.

Unia Europejska - bułgarski - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - Антинеопластични средства - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Unia Europejska - bułgarski - EMA (European Medicines Agency)

astrazeneca ab - гефитиниб - Карцином, недребноклетъчен белодроб - Антинеопластични средства - Иресса е показан за лечение на възрастни пациенти с локално-напреднал или метастазирал немелкоклеточным рак на белите дробове с активирането на мутации епидермален фактор на растежа-рецепторных тирозинкиназ.